Forte Biosciences Inc (NASDAQ:FBRX) — Market Cap & Net Worth
Market Cap & Net Worth: Forte Biosciences Inc (FBRX)
Forte Biosciences Inc (NASDAQ:FBRX) has a market capitalization of $172.07 Million ($172.07 Million) as of May 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17097 globally and #3849 in its home market, demonstrating a -2.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Forte Biosciences Inc's stock price $28.19 by its total outstanding shares 12432854 (12.43 Million). Analyse Forte Biosciences Inc cash conversion from operations to see how efficiently the company converts income to cash.
Forte Biosciences Inc Market Cap History: 2017 to 2026
Forte Biosciences Inc's market capitalization history from 2017 to 2026. Data shows change from $47.79 Billion to $350.48 Million (-43.12% CAGR).
Index Memberships
Forte Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.01% | #468 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1673 of 3165 |
Weight: Forte Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Forte Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Forte Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
69028.24x
Forte Biosciences Inc's market cap is 69028.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $47.79 Billion | $41.00K | -$38.93 Million | 1165580.06x | N/A |
| 2018 | $38.28 Billion | $18.04 Million | -$48.95 Million | 2122.29x | N/A |
| 2019 | $2.49 Billion | $36.00K | -$4.07 Million | 69028.24x | N/A |
Competitor Companies of FBRX by Market Capitalization
Companies near Forte Biosciences Inc in the global market cap rankings as of May 5, 2026.
Key companies related to Forte Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Forte Biosciences Inc Historical Marketcap From 2017 to 2026
Between 2017 and today, Forte Biosciences Inc's market cap moved from $47.79 Billion to $ 350.48 Million, with a yearly change of -43.12%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $350.48 Million | +3.37% |
| 2025 | $339.04 Million | +20.08% |
| 2024 | $282.35 Million | +10.51% |
| 2023 | $255.50 Million | -17.80% |
| 2022 | $310.82 Million | -53.27% |
| 2021 | $665.16 Million | -94.12% |
| 2020 | $11.32 Billion | +355.41% |
| 2019 | $2.49 Billion | -93.51% |
| 2018 | $38.28 Billion | -19.90% |
| 2017 | $47.79 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Forte Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $172.07 Million USD |
| MoneyControl | $172.07 Million USD |
| MarketWatch | $172.07 Million USD |
| marketcap.company | $172.07 Million USD |
| Reuters | $172.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Forte Biosciences Inc
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. … Read more